Robin Shattock has over 30 years’ experience in research and development of vaccines and antiviral therapeutics. He is a Professor of Mucosal Infection and Immunity at Imperial College, London.
His academic research portfolio includes vaccine projects on SARS-CoV2, HIV, Ebola, Lassa fever, Marburg and Rabies viruses and Chlamydia. He has a strong track record of translation research having taken a wide range of vaccine products through from discovery into clinical testing. The Shattock group was the first in the world to publish on the evaluation of a self-amplifying RNA vaccine against COVID-19 in phase I/II clinical trials. Robin leads the EPSRC Future Vaccines Manufacturing Research Hub at Imperial college. He is Founder of VaxEquity Ltd an Imperial spin-out focused on development of self-amplifying RNA. Robin is an elected fellow of the Academy of Medical Sciences.